



Recent Advances in Precision Medicine: Personalized Therapy, Drug Delivery and Nanomedicine

Guest Editors:

Prof. Dr. Liang Cheng

Brown University Warren Alpert
Medical School, Lifespan
Academic Medical Center,
Providence, RI, USA

Dr. Benedito A. Carneiro

Legorreta Cancer Center at
Brown University, Division of
Hematology/Oncology, The
Warren Alpert Medical School,
Providence, RI, USA

Dr. Chong-Xian Pan

Brigham and Women's Hospital,
Harvard Medical School, Boston,
MA, USA

Deadline for manuscript
submissions:

closed (1 October 2023)

Message from the Guest Editors

Dear Colleagues,

Personalized therapy is an emerging research area for disease treatment taking into account individual difference in genes, environment and lifestyles.


We hope to review the recent advances and upcoming technologies that will define how we can provide personalized treatment supported by individual patient or tumor molecular features or tailored to specific patient populations through targeted drug delivery. This Special Issue will cover established, new, and upcoming potential drugs, novel diagnostic modalities and therapeutic strategies, genomic discovery, nanomedicine, and cutting-edge technologies employed at all stages of target and drug discovery, validation, and delivery. It will also explore the role of machine learning in refining the understanding of mechanisms of resistance and signaling within complex pathophysiological systems.

We invite established investigators to contribute with original research and review articles. The submission deadline is May 1, 2023.

Sincerely,

Prof. Dr. Liang Cheng
Dr. Benedito A. Carneiro
Dr. Chong-xian Pan
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Senior Vice President and Director, Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Professor of Medicine Chief, Section of Hematologic Malignancies, Associate Director for Clinical Research, Division of Hematologic Malignancies and Cellular Therapy Duke Cancer Institute, Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access:— free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q2 (*Medicine, General & Internal*) CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[@JPM_MDPI](https://twitter.com/JPM_MDPI)